Navigation Links
Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
Date:5/6/2009

MONTREAL, May 6 /PRNewswire/ - Aegera Therapeutics is pleased to announce the initiation of a Phase 2a, proof-of-concept, clinical trial for AEG33773, a novel, orally bio-available small molecule therapeutic addressing the under-served market of painful diabetic neuropathy.

The Phase 2a study, entitled A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy will evaluate the efficacy, safety and tolerability of three dose levels of AEG33773 in diabetic patients suffering from significant neuropathic pain. This study is underway in Canada and Aegera will soon initiate trial sites in the Unites States, where the IND has recently cleared the FDA regulatory review process, and also in Europe, where the regulatory documents are now under review by the appropriate regulatory authorities.

"We are very excited about this first Phase 2 study for AEG33773 which has demonstrated robust preclinical in vivo data in multiple models of neuropathic and inflammatory pain. Furthermore, AEG33773 could have the potential to treat chronic pain conditions well beyond painful diabetic neuropathy." commented Dr. Jacques Jolivet, M.D., Senior Vice President Clinical Development of Aegera.

"With the successful conclusion of the Phase 1 safety studies for AEG33773 and the initiation of the first Phase 2a trial in diabetic patients suffering from significant neuropathic pain, we are now focused on successfully completing this trial while identifying an appropriate development partner; this will ensure that our novel agent is developed rapidly and effectively for its first indication while exploring additional indications so as to expand this franchise on a global basis." added Dr. Michael J. Berendt, Aegera's President and CEO.

About Aegera Therapeutics Inc. (www.aegera.com'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... Investor-Edge has initiated coverage on ... NBIX ), Insmed Inc. (NASDAQ: INSM ), ... Corporation (NASDAQ: DYAX ), and Oncothyreon Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced ...
(Date:10/25/2014)... Los Angeles, California (PRWEB) October 23, 2014 ... VDRM ), a specialty pharmaceutical company devoted to ... pursuing out-licensing partnerships in 2015. , ViaDerma has ... method, which allows for rapid mass transfer of ... into the body to provide immediate localized therapy. ...
(Date:10/25/2014)... 24, 2014 The Workgroup ... leading nonprofit authority on the use of health ... announces its appointment of four new co-chairs to ... leaders include:, ,     Peter Dumont, Senior ... Pupo, Specialist Leader, Deloitte Consulting LLP , ...
(Date:10/25/2014)... 2014 A new way to produce ... of current skin grafting technologies, it also speeds up ... method, outlined in the October issue of STEM CELLS ... skin injuries that result from severe burns and chronic ... skin’s regenerative elements. These wounds heal by contraction, with ...
Breaking Biology Technology:Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3
... works how people can tune in to a single ... solved this week in the journal Nature by ... Psychologists have known for decades about the so-called "cocktail ... in which it was coined. It is the remarkable human ...
... are single-cell plants that comprise nature,s smallest and ... thrive is water, light, and air. When bred ... to wastewater treatment to biofuels. Current microalgae breeding ... allowed by the laws of nature. Scientists at ...
... , Expanded clinical study ...   TMC435 and BMS-986094 (formerly ... in clinical trial , ... on the development of high-value treatments for infectious diseases, ...
Cached Biology Technology:How selective hearing works in the brain 2How selective hearing works in the brain 3Medivir Announces TMC435 in an Expanded Clinical Collaboration 2Medivir Announces TMC435 in an Expanded Clinical Collaboration 3Medivir Announces TMC435 in an Expanded Clinical Collaboration 4
(Date:10/29/2014)... compete with members of their own species. However, ... into their competitive ability. Some individuals are highly ... resources, while others seem to avoid competition, instead ... are left over for them. Moreover, the degree ... to fluctuate considerably over time. A theoretical study ...
(Date:10/28/2014)... in German . ... acquire sufficient food when times are lean? By studying ... d,Ivoire researchers of the Max Planck Institute for Evolutionary ... how great apes can acquire extra energy needed to ... their sleeping nests more en route to breakfast sites ...
(Date:10/28/2014)... be building a hybrid micro-grid which will integrate ... in the region, the hybrid micro-grid will test ... diesel, storage and power-to-gas technologies, and ensure these ... built under the new Renewable Energy Integration Demonstrator- ... located offshore at Semakau Landfill and is expected ...
Breaking Biology News(10 mins):Evolution of competitiveness 2Evolution of competitiveness 3The early chimp gets the fig 2The early chimp gets the fig 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3
... the growing demand for organic food products has led to ... of Science, University of Copenhagen, a European research project will ... of a food product and deciding whether or not it ... as olive oil, coffee and wine are sold at a ...
... Among overweight and obese adults, a diet rich ... and other high-fiber foods, significantly reduces markers of inflammation ... by Fred Hutchinson Cancer Research Center. Such a "low-glycemic-load" ... also increases a hormone that helps regulate the metabolism ...
... Every year, a group of anti-whaling nonprofit organizations that ... spend, by conservative estimates, some $25 million on a ... And every year, commercial whaling not only continues, but ... number of whales harvested annually has doubled since the ...
Cached Biology News:Research prevents eco-fraud 2Research prevents eco-fraud 3A diet rich in slowly digested carbs reduces markers of inflammation in overweight and obese adults 2Can we save the whales by putting a price on them? 2Can we save the whales by putting a price on them? 3
... Science Rotarods are used to assess the effect ... resistance on mice and rats using one unit ... friendly; the animals are placed on textured drums ... the individual sensing platforms below, its test results ...
... MultiScribe Reverse Transcriptase is a ... reverse transcriptase. MultiScribe Reverse Transcriptase is ... differs in its recommended usage. MuLV ... DNA polymerase that uses single-stranded RNA ...
... DNase I Amplification Grade ... DNA to oligodeoxyribonucleotides. The ... units/mg. DNAse I Amplification ... and tested for absence ...
... for the determination of digitonin and digoxin. Physical ... Na 4 and 0.06% NaCl Preparation Note: ... Biochem. Biophys. Res. Commun., 19, 755 (1965). ... of inorganic phosphorus from ATP per min at ...
Biology Products: